| US 7,527,933 B2 | ||
| Genetic products differentially expressed in tumors and the use thereof | ||
| Ugur Sahin, Mainz (Germany); Ozlem Türeci, Mainz (Germany); and Michael Koslowski, Köln (Germany) | ||
| Assigned to Ganymed Pharmaceuticals AG, , Mass. (US) | ||
| Appl. No. 10/537,002 PCT Filed Nov. 21, 2003, PCT No. PCT/EP03/13091 § 371(c)(1), (2), (4) Date May 20, 2005, PCT Pub. No. WO2004/047863, PCT Pub. Date Jun. 10, 2004. |
||
| Claims priority of application No. 102 54 601 (DE), filed on Nov. 22, 2002. | ||
| Prior Publication US 2006/0035852 A1, Feb. 16, 2006 | ||
| Int. Cl. G01N 33/53 (2006.01); G01N 33/574 (2006.01) | ||
| U.S. Cl. 435—7.1 [435/7.23] | 5 Claims |
| 1. A method of diagnosing lung, pancreatic, or esophageal cancer, comprising detecting expression of a tumor-associated antigen
in a biological sample, wherein the tumor-associated antigen is selected from the group consisting of:
(i) the polypeptide of SEQ ID NO: 16; and
(ii) the polypeptide encoded by the nucleic acid of SEQ ID NO: 7,
wherein detection of the tumor-associated antigen in a biological sample isolated from a patient in an amount greater than
an amount of the tumor-associated antigen in a normal biological sample indicates the presence of lung, pancreatic, or esophageal
cancer.
|